New clinical tool for clonal hematopoiesis identifies patients at high risk for blood cancer

Close Up Scientist using microscope in laboratory room while making medical testing and research

Clonal hematopoiesis (CH) is a recently characterized condition in which the genetic mutations associated with leukemia and other blood cancers are found in the blood of individuals without cancer. This pre-cancerous state is fairly common—for example, it’s present in roughly 15% of people over age 65—but only a small percentage, around 4%, will go on to develop blood cancer. Because there is no robust, rigorous way to assess risk, clinicians have struggled to advise CH patients on what the future could hold.

Save up to $150 on a range of Google Pixel products

Previous article

Study: Supermarket-based dietary education leads to healthier lives

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations